Search results
AbbVie (ABBV) Could Be a Great Choice
Zacks via Yahoo Finance· 3 days agoDividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?...
AbbVie Reports First-Quarter 2024 Financial Results
FOX 23 News Albany· 7 days agoReports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact ...
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 23 hours agoMerck & Co- $30.5bn Merck & Co’s revenues reached $60.1bn in FY 2023, with R&D investments peaking at $30.5bn. Displaying a staggering 126% growth...
New Cancer 'Missile' Drugs May Be More Effective Than Traditional Chemotherapy
Verywell Health via Yahoo News· 14 hours agoThe treatment, Elahere (mirvetuximab soravtansine), is for patients with late-stage disease who have...
Noninvasive Brain Stimulation Shows Rapid Relief for MDD
Medscape· 1 day agoAn RCT suggests transcranial alternating current stimulation may be an effective treatment for major...
Trials to watch: Four ALS drugs to keep an eye on
Clinical Trials Arena via Yahoo Finance· 3 days agoHEALEY Platform trial investigates Calico and AbbVie drug The HEALEY ALS Platform Trial (NCT04297683) is a perpetual multi-centre... is a Phase II/III...
Lower CVD Risk With Stable DMARD Therapy in Seropositive RA
Medscape· 1 day agoPatients with seropositive RA on stable DMARD therapy showed a CVD risk comparable with that of the...
Addex stock tanks after lead drug flops in Phase II epilepsy trial
Clinical Trials Arena via Yahoo Finance· 3 days agoThe use of PAMs for treating neurological disorders has been an area of focus in recent months. In...
Jacobio's KRAS data tee up safety-focused pitch for lung cancer market
FierceBiotech· 2 days agoJacobio Pharma is making a play for the Chinese KRAS market, unveiling registrational lung cancer...
JD Supra: Update on biosimilars in Canada – March 2024
JD Supra· 6 days agoIn this article, we provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, and market access) since our March...